

## Frequently Asked Questions (FAQs)

### **Who is Proventys?**

Proventys is a healthcare technology company developing advanced decision support solutions that help clinicians optimize treatment decisions at the point of care in oncology, cardiology and other areas.

### **Where is Proventys located?**

Proventys is headquartered in Newton, Mass.

### **What does Proventys do?**

Proventys develops novel predictive technologies and dynamic informatics tools to help clinicians navigate evidence-based guidelines, assess patient risks and deliver more personalized care.

### **What does Proventys strive to accomplish?**

As the volume of patient data and primary evidence available at the point of care continues to grow rapidly, Proventys aims to help clinicians access the information and technologies they need to simplify complex decisions.

### **What will be the benefits of using Proventys' advanced decision support solutions once they are available?**

Proventys' solutions will enable qualified healthcare professionals to access medical evidence and point-of-care tools efficiently, and help clinicians tailor treatment decisions to the characteristics of individual patients. By doing so, Proventys' solutions will help increase the overall quality of care and reduce unnecessary expense.

### **Are Proventys' technologies regulated by the FDA?**

Proventys is currently developing two distinct product lines that provide advanced decision support to clinicians at the point of care, focused first in oncology: Proventys PDx Oncology™ and Proventys CDS Oncology™. Proventys PDx Oncology is a novel medical device that delivers software-based predictive tests targeting specific clinical events. Its lead predictive test, the FN PDx™, assesses an adult cancer patient's individualized risk of febrile neutropenia (FN), a serious adverse event of chemotherapy. The product is under review by the FDA (de novo) and not available for sale in the United States.

Proventys CDS Oncology™ system is a clinical decision support platform that dynamically renders the NCCN Guidelines™ and prompts clinicians with suggested treatment options based on individual patient characteristics. This product is being developed in collaboration with the National Comprehensive Cancer Network (NCCN) and is a clinical informatics system (not a regulated medical device).

### **Where can I learn more about Proventys and its predictive solutions?**

For more information, please visit the Proventys Website at [www.proventys.com](http://www.proventys.com).